AstraZeneca slumps on report CEO is heading to Teva

AstraZeneca slumps on report CEO is heading to Teva


Shares in AstraZeneca fell more than 5 percent on Thursday after the company declined to deny a media report that Chief Executive Pascal Soriot was about to defect to Israel-based Teva Pharmaceutical Industries. Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014.



from Biotech News